This study aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model for C.E.R.A., a continuous erythropoietin receptor activator. C.E.R.A. is administered via intravenous (IV) and subcutaneous (SC) routes once every 2 weeks (Q2W) or once every 4 weeks (Q4W), respectively, to correct or maintain hemoglobin levels in chronic kidney disease (CKD) patients.
May 1, 2010
Author(s): Pascal Chanu, Ronald Gieschke, Jean‐Eric Charoin, Anne Pannier, Bruno Reigner
Year: May 1, 2010